Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

Learn how experts leverage BTK inhibitors for optimal management of patients with MCL, CLL, and other B-cell malignancies in this CME-certified, on-demand Webcast of a dynamic CCO symposium at ASH 2019.

Ian W. Flinn, MD, PhD
Program Director Jan A. Burger, MD, PhD Alexey Danilov, MD John Pagel, MD, PhD Physicians: maximum of 2.75 AMA PRA Category 1 Credits™ Released: February 4, 2020 Expired: No longer available for credit

With 2 BTK inhibitors currently approved for various hematologic malignancies, I will discuss the rationale and importance of continuing to develop additional agents in this class and what we hope to achieve.

John Pagel, MD, PhD Released: October 24, 2019

At our recent symposium at the 2019 ASH meeting, my colleagues and I discussed our perspectives on the use of BTK inhibitor therapy for B-cell malignancies. Here I have provided insights into to some of the major themes asked on this topic.

Ian W. Flinn, MD, PhD Released: February 21, 2020

Are you ready to include BTK inhibitor zanubrutinib as a treatment option for patients with MCL in your practice?

John Pagel, MD, PhD Released: March 24, 2020

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with hematologic malignancies.

Alexey Danilov, MD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on frontline of BTK inhibitors to review the most current clinical data on treating patients with MCL

Ian W. Flinn, MD, PhD
Program Director Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on frontline use of BTK inhibitors to review the most current clinical data on treating patients with CLL

John Pagel, MD, PhD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with diverse hematologic malignancies.

John Pagel, MD, PhD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on overcoming resistance to BTK inhibitors to review the most current clinical data on treating patients with CLL.

Jan A. Burger, MD, PhD Released: December 6, 2019